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Several studies suggest that microbial alterations (dysbiosis) are intimately linked to chronic 
inflammation occurring upon aging. The aim of this study was to investigate the potential interest of a 
synbiotic approach (co‑administration of a probiotic bacteria and a prebiotic dietary fibre) to improve 
gastrointestinal wellness and inflammatory markers in middle‑aged people. Middle‑aged subjects 
were randomized to take synbiotic (Bifidobacterium animalis lactis and fructo‑oligosaccharides (FOS)) 
or placebo for 30 days. Stool frequency and consistency were improved in both placebo and synbiotic‑
treated volunteers while the synbiotic treatment significantly decreased the number of days with 
abdominal discomfort. Synbiotic treatment had no impact on mood dimensions, quality of life scores 
or the overall composition of the gut microbiota (16S rRNA gene sequencing of DNA extracted from 
stool). Importantly, plasma proinflammatory cytokines (interleukin (IL)‑6, IL‑8, IL‑17a and interferon‑
gamma (IFNγ)) were significantly lower after 30 days of synbiotic supplementation. This effect appears 
to be independent of the gut barrier function. This study demonstrates that a combination of B. 
animalis lactis and the well‑known prebiotic FOS could be a promising synbiotic strategy to decrease 
inflammatory status with improvement of gut disorders in middle‑aged people.
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NAFLD  Nonalcoholic fatty liver disease
PGI-I  Patient Global Impression of Improvement survey
PCS  Physical Component Score
SBP  Systolic blood pressure
SF12  12-Item short form survey
VAS  Visual analogue scales
The absolute number and the proportion of older people is increasing in most countries, with a continued rise 
in life  expectancy1. Population ageing is particularly rapid within the European Union, due to low fertility rates 
and decreasing old age  mortality2. Several health problems can be present or aggravated with ageing, which can 
compromise the quality of life. It is the case of constipation, one of the most frequent gastrointestinal disorders 
encountered in clinical practice in Western  countries3. Importantly, chronic constipation is associated with 
significant impairment to quality of  life4, represents a burden to healthcare delivery systems and results in large 
individual healthcare  costs5,6. Constipation prevalence increases with age in women versus  men3,7. Although 
laxatives are effective and commonly used in most patients, several side effects can often occur, especially with 
chronic use, which limits their use in the  elderly8.
The availability of new, effective and safe treatments for chronic constipation without side effects would 
improve quality of life and the health status of the elderly.
Aging is also associated with a disruption of the immune system, including the release of several pro-inflam-
matory markers into the bloodstream, a phenomenon that has been called “inflammaging”. Indeed, many studies 
show that circulating concentrations of many inflammatory mediators are higher in the elderly than in young 
 adults1,9. It is important to note that a previous report showed that subclinical elevations of inflammatory mark-
ers such as interleukin-6 (IL-6) are linked to the development of diabetes in middle-aged adults, demonstrating 
that low-grade systemic inflammation precedes and predicts the development of diabetes in  adults10. Different 
tissues (adipose tissue, muscle), organs (liver and brain), systems (immune system) and ecosystems (intestinal 
microbiota) may contribute to the systemic state of low-grade inflammation observed during aging by altering 
the production of pro-inflammatory and/or anti-inflammatory  mediators1.
The gut is populated by trillions of bacteria, archaea, eukarya, and viruses, constituting the gut microbiota. 
Five major microbial phyla (Firmicutes, Bacteroidetes, Proteobacteria, Verrucomicrobia and Actinobacteria) 
account for 98% of the intestinal  microbiota11,12. Microbiota composition was a strong co-variate of measures 
of comorbidity, nutritional status, and markers of inflammation and microbial dysbiosis has been recently pro-
posed as an additional hallmark and biomarker of  aging13–15. Whether changes in gut microbiota are a cause or 
a consequence of aging in itself remains an exciting and challenging question. What has been demonstrated is 
that some gut bacteria promote aging-associated inflammation and that reversing microbiota dysbiosis repre-
sents an interesting therapeutic approach to reduce  inflammation9. Microbiota-driven therapies, such as intake 
of probiotics, prebiotics or synbiotics, seem a promising approach to control inflammation increasing with 
age. Probiotics are specific microorganisms which have a beneficial effect on host  health16 whereas prebiotics 
are nutrients selectively utilized by specific gut bacteria that confer health benefits to the  host17,18. The admin-
istration of probiotics or prebiotics has been proposed as an innovative and valid alternative for functional or 
chronic constipation compared to traditional treatments with  drugs3,19–21. The combination of selected probiotics 
and prebiotics can fit lead to the concept of “synbiotics”—which has been proposed as innovative therapeutic 
approach. A panel of nutritionists, physiologists and microbiologists recently updated the definition of a synbiotic 
to “a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that 
confers a health benefit on the host”22. Although previous animal studies have demonstrated that microbiota-
driven therapy changed the composition of the gut microbiota and decreased inflammatory  markers23, whether 
this benefit can be translated to human remains controversial.
In the present study, we investigated the effects of a synbiotic-combining fructo-oligosaccharides (FOS) and 
Bifidobacterium animalis lactis—as an emerging strategy to improve intestinal transit and to relieve the symptoms 
of constipation in middle-aged people. In addition, we explored the gut microbiota, the quality of life and the 
inflammatory status as secondary endpoints.
Results
Baseline characteristics. Twenty-seven subjects (n = 27) were randomized for the study: 14 in the pla-
cebo group and 13 in the synbiotic group. The average age was 58 ± 6 years. The majority of the subjects (85%) 
included in this study were women. At baseline, the groups were similar in terms of age, sex, weight, blood 
pressure, serum transaminases, triglyceridemia, cholesterolemia and glycemia (Table 1). The compliance with 
consuming the study product was 94.9% and 96.7% for placebo and synbiotic, respectively. None presented 
major deviations from the protocol and all participated until the end of the study. Under these circumstances, 
the per protocol (PP) and intention to treat (ITT) results of the study were identical as they related to the same 
population.
Primary outcome. Middle-aged subjects had experienced transit disorders for 17.8 ± 15.4 years on average 
and in the previous 2 weeks they had experienced pain on average on 2.9 ± 4.2 days. This pain was associated 
with feeling bloated in 55.6% of subjects and gas in 51.9% of them but never with diarrhea or liquid stools. Nearly 
one in five subjects (18.5%) had already taken treatments for transit, essentially laxatives of some sort. The aver-
age number of daily bowel movements observed in the reference period before taking the products under study 
was 0.4 ± 0.1 per day, that is, 2.6 ± 0.5 per week whereas stool consistency was 2.6 ± 0.9. After intervention, two 
of the Rome III diagnostic criteria for constipation were improved—stool frequency and consistency—over 
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time whatever the treatments (placebo or synbiotic; Fig. 1a,b). In addition, the number of days with abdominal 
discomfort decreased in both groups but this effect was significant only after the treatment with the synbiotic 
(Fig. 1c). Symptoms accompanying abdominal pain or discomfort such as diarrhea, bloating or gas were not dif-
ferent between the treatments (Supplementary Table S1). 31% of the subjects in the synbiotic group, versus 14% 
Table 1.  Baseline characteristics of participants. Values are means ± SD. Baseline data were analyzed by 
Mann–Whitney test for continuous variables (p > 0.05) and Fisher test for categorical variables (ratio women/
men; p > 0.05). ALAT alanine aminotransferase, ASAT aspartate aminotransferase, BMI body mass index, DBP 
diastolic blood pressure, SBP systolic blood pressure.
Placebo (n = 14) Synbiotic (n = 13) All (n = 27)
Women/men N (%) 12/2 (86/14) 11/2 (85/15) 23/4 (85/14)
Age (years old) 58 ± 7 58 ± 5 58 ± 6
Body weight (kg) 64.5 ± 11.4 69.1 ± 10.9 66.7 ± 11.2
BMI (kg/m2) 23.8 ± 3.2 24.7 ± 3.4 24.3 ± 3.3
SBP (mm Hg) 118.2 ± 15.8 118.2 ± 18.3 118.5 ± 16.7
DBP (mm Hg) 73.6 ± 6.6 75.8 ± 9.1 74.6 ± 7.8
ALAT (UI/l) 19.4 ± 6.1 24.8 ± 8.6 22.0 ± 7.7
ASAT (UI/l) 21.6 ± 4.2 24.1 ± 5.5 22.8 ± 4.9
Glycemia (g/l) 0.93 ± 0.10 0.97 ± 0.10 0.95 ± 0.10
Triglyceridemia (g/l) 0.96 ± 0.37 0.98 ± 0.43 0.97 ± 0.39
Cholesterolemia (g/l) 2.35 ± 0.40 2.38 ± 0.38 2.37 ± 0.39
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57.14%  Slightly improved
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23.08%  Much improved
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7.69%  Significantly improved
7.69%  Slightly worse
Synbiotic
Patient Global Impression of
Improvement (PGII)
Figure 1.  Transit characteristics in middle-aged adults receiving placebo or synbiotic for 30 days. Values are 
means ± SEM except for d (placebo: n = 14, synbiotic: n = 13). Mixed model ANOVA were performed to compare 
evolution of stool frequency and consistency (time effect: *p < 0.05). Matched-pairs Wilcoxon signed-rank test 
was performed for the number of days with abdominal discomfort to compare changes from baseline (*p < 0.05). 
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in the placebo group, reported a significantly or much improved perception of change about the transit (accord-
ing to the PGI-I questionnaire) (Fig. 1d).
Secondary outcomes. The change of habitual diet determined through a survey (established according to 
the recommendations of the French National Nutrition and Health Program (PNNS)) was not different between 
the groups except for sweetened foods (Supplementary Table S2). Indeed, we observed that the evolution in 
sweetened food intake was different between groups (30% of subjects consumed more sweetened food after 
30 days of synbiotic supplementation whereas 21% of subject decreased this intake after placebo treatment). 
Of note, there was no difference in the evolution of water intake between groups. For the whole population, the 
Mental Component Score (MCS) was 47.4 ± 9.4 and the Physical Component Score (PCS) was 52.2 ± 6.5; both 
determined according the SF12 questionnaire. There was no significant difference between treatments regarding 
these scores (Table 2). In addition, mood tests did not show any significant general improvement whatever the 
items of the Brief Mood Introspection Scale (BMIS) or the groups considered (Supplementary Fig. S1). Figure 2 
shows that there was no significant improvement in the four mood subscales over time whatever the treatments 
considered. However, it is worth noting that the scores for the Pleasant-Unpleasant dimension and Positived-
Tired were higher in the synbiotic group whereas the scores for Arousal-Calm dimension and Negative-Relaxed 
mood dimension were lower in the synbiotic group compared to placebo group (except after 1 week of treatment 
where the scores were similar in both groups) (Fig. 2).
Analysis of plasma inflammatory markers revealed that the synbiotic intervention impacted systemic inflam-
mation. Indeed, the levels of IL-6, IL-8, IL-17a and IFNγ were significantly lower 30 days after synbiotic treat-
ment as compared to the basal values (Fig. 3). This effect was not present in the placebo group and seemed to 
be independent of the gut permeability as suggested by the lack of significant effect on fecal albumine or plasma 
intestinal fatty acid binding protein (iFABP) whatever the treatment considered (Supplementary Fig. S2).
As shown in Fig. 4, there were no statistically significant differences in the alpha and beta diversities plots 
after 30 days of placebo or synbiotic. Coherently, the relative abundance of the most abundant phyla, family and 
genera were unchanged by the treatments (data not shown).
Discussion
It has already been suggested that constipation associated with advanced age is an adequate condition for observ-
ing an improvement of intestinal transit time after probiotic  supplementation19. A meta-analysis conducted in 
2017 and updated in  201924,25 has concluded that synbiotics have a positive effect on bowel movement frequency 
and stool consistency. It should be noted that all studies using FOS or B. animalis in the synbiotic combinations 
were performed in adults below 40 years. Therefore, the primary objective of our randomized, double-blind, 
controlled clinical trial was to test the influence of a synbiotic combination composed of FOS and Bifidobacterium 
animalis subsp. lactis. in older healthy volunteers with infrequent bowel movements (but not severe constipation). 
The selected probiotic and prebiotic have been often tested alone showing an improvement in intestinal transit 
especially in the  elderly26,27. Consistent with a more recent study performed in subjects of 45 years old treated with 
B. animalis subsp. lactis and  inulin28, the present study reports that stool frequency and consistency improved 
over time whatever the treatment (placebo or synbiotic) in subjects with a mean age of 58 years. Importantly, 
the number of days with abdominal discomfort decreased only in the synbiotic group and 30% of the subjects 
perceived significant improvement of their gut transit time after the synbiotic treatment.
Dysbiosis in functional constipation (Rome III criteria) were recently  reviewed25. In particular, Khalif et al. 
demonstrated that patients with functional constipation (mean age 42 years) had a reduced level of Bifidobac-
terium, Lactobacillus, Bacteroides, and Clostridium species and an increased level of Enterobacteriaceae, such as 
Escherichia coli, as well as Staphylococcus aureus and  fungi29. This study and other published data therefore suggest 
that constipation is associated with gut dysbiosis, and that gut motility can be managed by modulation of gut 
Table 2.  Mental and physical wellbeing according to Short-Form 12-item (SF-12) questionnaire in middle-
aged adults receiving placebo or synbiotic for 30 days. Values are means ± SD (placebo: n = 14, synbiotic: 
n = 13). Matched-pairs Wilcoxon signed-rank tests were performed to compare changes from baseline (within-
group variations; p > 0.05). Between-groups variations were analyzed by Mann–Whitney U-tests (p > 0.05).
Placebo Synbiotic
Baseline Day 30 Baseline Day 30
Mental Component Score (MCS) 45 ± 10.8 46.8 ± 11.3 50 ± 7.2 48.4 ± 5.8
Physical Component Score (PCS) 51.5 ± 7.9 50.6 ± 6.1 52.9 ± 5 54.1 ± 4.2
Physical function 87.5 ± 23.5 89.3 ± 18.9 94.2 ± 15 94.2 ± 11
Role physical 85.7 ± 18.9 84.8 ± 18.5 92.3 ± 10.9 95.2 ± 9.6
Bodily pain 78.6 ± 23.7 83.9 ± 23.2 90.4 ± 12.7 94.2 ± 11
General health 65.4 ± 10.6 62.9 ± 15.2 66.9 ± 13.6 68.1 ± 15.8
Vitality 33.9 ± 21 28.6 ± 25.7 46.2 ± 13.9 38.5 ± 21.9
Social function 89.3 ± 16.2 83.9 ± 23.2 90.4 ± 12.7 90.4 ± 12.7
Role emotional 75.9 ± 19.3 84.8 ± 18.5 92.3 ± 10.9 90.4 ± 11.6
Mental health 66.1 ± 23.2 66.1 ± 23.2 74 ± 15.7 73.1 ± 13.4
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 microbiota30–32. Others reported that relief of constipation by laxatives tend to normalize and restore microbiota 
composition, thus suggesting that dysbiosis is a consequence, rather than a cause of  constipation29. In the current 
study, we did not find any changes in the relative abundance of the most frequent phyla, family and genera in this 
middle-aged population who met Rome III criteria for constipation in the synbiotic nor placebo treated groups. 
This suggests that the gut microbiota composition was not relevant in the improvement of the stool frequency 
and consistency or abdominal discomfort pinpointed in the present study. This lack of association was already 
reported in a randomized, placebo-controlled trial testing the effects of inulin on stool frequency, gut microbiota 
composition and quality of life in middle-aged to older  populations21. This study demonstrated that inulin (10 g/
day) improved stool frequency and consistency without significant changes in gut microbiota composition after 
5 weeks of treatment. We cannot exclude however that bacterial species below the limit of detection of 16S rDNA 
sequencing may be affected by the synbiotic and may contribute to the observed benefits.
A decline in the quality of life related to constipation and bowel-related symptoms has been reported and 
reached the same extent as some chronic conditions like  diabetes4,33. Therefore, we assessed quality of life using 
the SF12 survey. This questionnaire allowed us to evaluate the level of eight health concepts including compo-
nents of both physical and mental health. Synbiotic supplementation or placebo treatment did not change any 
of these eight categories meaning that both interventions did not improve neither physical health nor mental 
health of participants. In line with this result, although four different dimensions calculated from BMIS ques-
tionnaire tended to be improved by the synbiotic treatment, none of those revealed significant impact of dietary 
supplementations on subject mood.
Previous studies have demonstrated that older individuals with higher levels of inflammatory markers are 
more likely to develop a variety of late-life diseases, accompanied by a higher hospitalization rate and all-cause 
mortality rate 13. Of particular interest, one study, consistent with previous investigations, demonstrates that 
subclinical elevations of inflammatory markers, in particular IL-6, are associated to the development of diabetes 
in middle-aged  adults10. Several studies have suggested the potential contribution of microbiota-driven therapies 
to improve inflammatory states in inflammatory bowel disease, obesity and type 2  diabetes9,34–37. In addition, 
other studies also showed a benefit of microbiota-driven therapies, including synbiotic in elderly individuals 
(> 60 years), in the context of inflammatory  disorders38,39. Although previous animal studies have demonstrated 
a benefit of microbiota-driven therapies to decrease low grade chronic inflammation in aged individuals, it 
remains controversial in human  interventions9,23. A systematic review conducted in 2019 investigated the effect 
of microbiota-driven therapies in randomized controlled trials on inflammatory markers in elderly individuals. 
























































Figure 2.  Mood subscales determined according to the Brief Mood Introspection Scale (BMIS) in middle-aged 
adults receiving placebo or synbiotic for 30 days. Values are means ± SEM (placebo: n = 14, synbiotic: n = 13; 
p > 0.05; mixed model ANOVA).
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Figure 3.  Plasma inflammatory markers in middle-aged adults at baseline (light color) or after receiving 
placebo or synbiotic for 30 days (dark color). Individual values and means are presented (placebo: n = 14, 
synbiotic: n = 13). Matched-pairs Wilcoxon signed-rank tests were performed to compare changes from baseline 
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The authors concluded that after treatment, no differences were observed between microbiota-driven therapy 
group and placebo group in the levels of key proinflammatory cytokines such as TNF-α, IL-1β, IL-6 and IL-89. 
In the present study, we observed that the synbiotic combination decreased the key cytokine IL-6 among other 
proinflammatory markers (IL-8, IL17a and IFNγ) after only 30 days of treatment in healthy middle-aged vol-
unteers without any suspicion of type 2 diabetes mellitus and cardiovascular diseases. This anti-inflammatory 
effect seemed to be independent of the gut barrier integrity as suggested by the lack of significant effect on fecal 
albumine or plasma  iFABP40. Recent papers propose that intestinal bacterial metabolites modulate inflammation 
and gene expression, notably in the liver (for review,  see35). An important clinical trial in in nonalcoholic fatty 
liver disease (NAFLD) patients consuming 4 g FOS twice daily combined with B. animalis subsp. lactis BB-12 
(INSYTE study) has demonstrated that changes with this synbiotic in specific microbes known to be involved 
in the regulation of the inflammatory tone occur without clinically significant effects on the liver. This supports 
a need to evaluate the effect of synbiotic treatment on inflammatory/immune-related parameters in  NAFLD41. 
Along these lines, another study showed that the consumption of a yogurt containing B. animalis subsp. lactis 
produced intestinal bacterial metabolites that contribute to suppression of inflammatory cytokines produced by 
macrophages. One of the anti-inflammatory metabolites in the fecal extracts was likely a  polyamine42.
Importantly, IL-17 plays a crucial role in sustaining chronic inflammation and its over-expression has been 
found in a number of inflammatory disorders, including inflammatory bowel  disease43. Ligation of IL-17 with its 
receptor may induce IL-6 and IL-8 production through mitogen-activated protein kinase pathways, thus favoring 
the recruitment of neutrophils at sites of inflammation, and triggers T cell proliferation and upregulation of a 
number of pro-inflammatory molecules.
We have identified several limitations to our study. First, the treatment lasted 30 days. De facto, the effect of 
a longer term synbiotic supplementation on (gastrointestinal) wellness and inflammation is unknown. Secondly, 
a study with a higher number of participants and a cross-over design would increase the statistical power of 
the analyses. Thirdly, knowing that gender may impact outcomes related to constipation or the prevalence and 
severity of constipation in the elderly, this parameter should be tested as possible effect modifiers by choosing 
for example to enroll higher number of subjects with control, power and randomization for gender in a future 
cross-over  study44. Research is needed on gender and age differences in the symptoms of constipation, and 
how covariates impact the prevalence and severity of constipation in the elderly. Fourthly, the gastrointestinal 
























































































Figure 4.  Alpha-diversity indexes (a–c) and principal coordinates analysis of the β-diversity index, Bray–Curtis 
(d) of the gut microbiota in middle-aged adults at baseline or after receiving placebo (n = 14) or synbiotic 
(n = 13) for 30 days. Data are mean ± SD. For α-diversity indexes, matched-pairs Wilcoxon signed-rank tests 
were performed to compare changes from baseline (within-group variations; p > 0.05). For β-diversity index, 
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symptoms such as discomfort, nausea, flatulence, cramp, burp, bloating, rumbling and reflux were not investi-
gated on visual analogue scales (VAS). Nevertheless, we can conclude a combination of B. animalis subsp. lactis 
with the well-known prebiotic FOS could be a promising synbiotic strategy to decrease inflammatory status with 
improvement of gut disorders in middle-aged people that experienced episodes of constipation. In line with the 
current literature, we propose that the early treatment of systemic inflammation through microbiota-driven 
therapies such as synbiotics may improve prognostic of chronic inflammatory-dependent disorders such as 
inflammatory bowel disease, type 2 diabetes mellitus and cardiovascular  diseases45.
Methods
Power analysis and sample size. The sample size assumes a difference of 1 in the average change in stool 
frequency per week between the synbiotic group and the placebo group. For the randomized, placebo-con-
trolled study design and using the outcome measures described in the study protocol, the calculation performed 
(with Nquery Advisor software version 7.0; https ://www.stats ols.com/nquer y), with a standard deviation of 1, 
an increase of 0.5 stools per week in the placebo group and 1.5 stools in the synbiotic groups at risk alpha = 0.05, 
with a power of 80 and in a unilateral situation, gives a number of subjects to introduce of 13 per arm (30 subjects 
in total to take into account the loss of sight and the non-exploitable files).
Clinical study. This prospective, randomized, double-blind, placebo-controlled study was designed accord-
ing to the CONSORT 2010 guidelines and was conducted at the CEN Nutriment, a Contract Research Organiza-
tion in France (Dijon) from March 2017 to March 2018. The study was approved by the Comité de Protection 
des Personnes (Dijon, France; Approval Number: 2016-A00970-51) prior to implementation. The trial study 
was listed on the NIH ClinicalTrials.gov website (NCT04283266; 25/02/2020). No changes were made to this 
trial after recruitment of the participants commenced. The author ensure that the study has been carried out in 
accordance with The Code of Ethics of the World Medical Association and followed the ethical guidelines set 
out in the Declaration of Helsinki. All participants provided written informed consent in compliance with the 
European law 2001/20/CE guidelines.
The allocation sequence to either placebo or study product was based on random sequence generated using 
MS EXCEL (simple randomization). The products were distributed to subjects in accordance with the randomi-
zation list. The randomization key, indicating to which products the batches given to patients corresponded to, 
was kept in a sealed envelope. The coordinator and nurse enrolled participants and assigned them to placebo or 
synbiotic (computer-generated randomized numbers). Participants, care providers, researchers involved in data 
analyses were blinded to which arm participants were assigned. All information collected was kept in a secured 
area and sent for statistical analyses with a study number and without participant identifiers.
An overview of the study design is shown in Fig. 5. Forty subjects were recruited. Among them, 13 subjects 
were excluded from the analysis because they did not meet the inclusion criteria. Twenty-seven received allocated 
intervention and completed the study (Supplementary Fig. S3). The inclusion criteria and exclusion criteria 
were given in “Supplementary Methods S1”. Of note, knowing that physical exercise may affect gut  transit46, the 
volunteers were instructed not to change their physical activity habits during the study.
The primary endpoint of this trial is to evaluate the effect of synbiotic supplementation on intestinal transit 
of subjects. The secondary endpoints are to evaluate changes in stool appearance, quality of life and mood, relief 
and satisfaction of participants, changes in food consumption (survey with items according to recommenda-
tions of French National Nutrition and Health  Program47) and changes in low-grade chronic inflammation and 
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Figure 5.  Overview of the clinical study. BMIS Brief Mood Introspection Scale, BSFS Bristol Stool Form Scale; 
SF12 12-item short form survey measuring the eight health domains for adults (providing psychometrically-
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Intervention. The subjects received daily two bags of either synbiotic (Bifidobaterium animalis lactis Vesa-
lius 002 (LMG P-28149) 5.109 bacteria/bag + fructo-oligosaccharides (FOS, ACTILIGHT, 4.95 g/bag) or placebo 
(maltodextrin 60%, sucrose 40%; 5 g/bag) for 5 days, then they received daily 1 bag for the next 25 days. As 
already described for other strains of Bifidobaterium animalis lactis48, this strain is resistant to the stomach 
or small intestinal environment (data not shown). Bags were prepared by Vesale Pharma (Belgium) and were 
strictly identical in appearance. Placebo powder contained only excipients (maltodextrin 60%–saccharose 40%). 
The white powder was also similar in appearance, was odorless and had similar sweet taste for both packaging. 
Subjects received 50 bags in total but only 35 were required to complete the study; unused bags were returned 
to measure compliance (calculation: (50 − number of bags that were returned) × 100/35). The sachets were to be 
dissolved in 200 ml of water at room temperature to be taken before breakfast.
Transit characteristics. The stool frequency and consistency were investigated through daily self-assess-
ment using the Bristol Stool Form Scale (BSFS)49, a simple tool for estimating intestinal transit time, from 
2 weeks before the enrolment visit (run-in period) until the end of the intervention. The BSFS classifies stools 
into seven categories, including type 1, separate hard lumps, like nuts; type 2, sausage-shaped, but lumpy; type 3, 
like a sausage but with cracks on the surface; type 4, like a sausage or snake, smooth and soft; type 5, soft blobs 
with clear-cut edges; type 6, fluffy pieces with ragged edges, a mushy stool; type 7, watery, no solid  pieces50. These 
types are categorized into slow transit (types 1 and 2), normal transit (types 3–5), and fast transit (types 6 and 7).
A questionnaire was submitted at baseline (d-14) and after intervention (d30) in order to evaluate the num-
ber of days with abdominal pain and intestinal discomfort evolution (accompanied or not with symptoms of 
diarrhea, bloating or gas). Patient Global Impression of Improvement (PGI-I) survey was also submitted at the 
end of the treatment (day 30); the PGI-I is a 1-item questionnaires asking to rate the perceived change in his/
her condition in response to therapy at  endpoint51.
Mood assessment. Mood alterations was investigated through daily self-assessment using the Brief Mood 
Introspection Scale (BMIS), consisting of 16 mood adjectives (Lively, Drowsy, Happy, Grouchy, Sad, Peppy, 
Tired, Nervous, Caring, Calm, Content, Loving, Gloomy, fed up, Jittery, Active)52. Subjects were asked to circle 
the phrases describing their present mood (with XX = definitely do not feel; X = do not feel; V = slightly feel; 
VV = definitely feel on the diverse adjectives). The BMIS was scored for Pleasant-Unpleasant Mood, Arousal-
Calm Mood, Positive-Tired Mood and Negative-Relaxed Mood according to the Mayer’s  method53.
Quality of life assessment. Mental and physical wellbeing were assessed before (d-14) and after interven-
tion (d30) through the Short-Form 12-item (SF-12) questionnaire consisting of 12 questions relating to: physi-
cal health problems, bodily pain, general health perceptions, vitality (energy/fatigue), social functioning, role 
limitations and general mental health (psychological distress and psychological well-being)54,55. This instrument 
yields two summary scores: a Mental Component Score (MCS), and a Physical Component Score (PCS). The 
SF12 takes 2 min to administer and has been validated for use with elderly people.
Plasma analysis. The blood samples collected before (d-14) and after intervention (d30) were immediately 
centrifuged and plasma was transferred and kept at − 20 °C until analysis. Biochemical parameters including 
alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) concentrations were measured using 
standard laboratory techniques. Blood for peptide analysis was immediately transferred into specific tube (BD 
P800 Blood Collection System (BD Biosciences, CA, USA). Plasma obtained for inflammatory markers and pep-
tides were transferred at − 80 °C before analysis. Plasma cytokines (interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-17a, 
monocyte chemotactic protein-1 (MCP-1), interferon (IFN) γ and tumor necrosis factor (TNF) α) and plasma 
peptides (pancreatic polypeptide (PP), glucose-dependent insulinotropic peptide (GIP), leptin, ghrelin, insulin) 
were determined in duplicate by multiplex immunoassays (Millipore, Belgium) and measured using LUMINEX 
xMAP technology (Biorad, Nazareth, Belgium) following the manufacturer’s instructions.
Gut microbiota analyses. Stool samples were collected at baseline and at the end of the 30-days of inter-
vention (one fecal sample collected and stored at − 20 °C within 7 days before day 0 and before day 30) and trans-
ferred to − 80 °C for the analysis of the gut microbiota composition. Genomic DNA was extracted from faeces 
using a PSP spin stool plus DNA kit (Stratec biomolecular, Berlin, Germany), according to the manufacturer’s 
instructions. 16S rDNA profiling, targeting V1–V3 hypervariable region and sequenced on Illumina MiSeq were 
performed as described  previously56.
Statistical analysis. Data are expressed as mean ± SD for tables and mean ± SEM for figures. Between 
group differences were analyzed by Fisher or Chi Square tests for categorical variables or Mann–Whitney test 
for continuous variables. Within group analyses were evaluated using a Wilcoxon paired test (from baseline to 
30 days of intervention). Mixed model ANOVA by Sidak’s multiple comparisons test were performed to com-
pare effects over time. A significance level of p < 0.05 was used for all the analyses. For gut microbiota analysis, 
p-values of within group comparisons were corrected to control for the false discovery rate (FDR) for multiple 
tests according to the Benjamini and Hochberg procedure and a significance level of q < 0.1 was used. All analy-
ses were conducted with, Graphpad Prism software version 8 (San Diego, USA; www.graph pad.com) except for 
the gut microbiota analysis where we used R version 3.5.2.
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